LGVN · Longeveron Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.20M | $2.39M | $709.0K | $1.22M | $5.63M |
| Cost of Revenue | $396.0K | $508.0K | $488.0K | $725.0K | $3.80M |
| Gross Profit | $803.0K | $1.88M | $221.0K | $497.0K | $1.83M |
| R&D | $12.04M | $8.14M | $9.07M | $9.37M | $2.67M |
| SG&A | $12.05M | $10.27M | $11.40M | $8.12M | $2.73M |
| Total Operating Expenses | $24.09M | $18.41M | $21.25M | $18.54M | $5.60M |
| D&A | $800.0K | $700.0K | $700.0K | $1 | $1 |
| Operating Income | ($23.29M) | ($16.52M) | ($21.03M) | ($18.04M) | ($3.78M) |
| Interest Expense | - | - | - | $1.40M | $7.0K |
| Income Tax | $0 | $0 | $0 | - | - |
| Net Income | ($22.70M) | ($15.97M) | ($21.41M) | ($18.84M) | ($17.05M) |
| EPS - Basic | ($1.29) | ($2.62) | ($10.20) | ($9.00) | - |
| EPS - Diluted | ($1.29) | ($2.62) | ($10.20) | ($9.00) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $4.66M | $19.23M | $4.95M | $10.50M | $25.66M |
| Accounts Receivable | $104.0K | $84.0K | $111.0K | $55.0K | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | $423.0K | $99.0K | $638.0K | - | $645.0K |
| Current Assets | $5.45M | $19.62M | $5.85M | $20.28M | $35.38M |
| Total Assets | $10.26M | $25.56M | $12.08M | $27.41M | $42.77M |
| Current Liabilities | $4.09M | $2.58M | $3.89M | $4.87M | $2.71M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $4.59M | $3.67M | $5.34M | $6.91M | $5.31M |
| Stockholders' Equity | $5.67M | $21.89M | $6.74M | $20.50M | $37.45M |
| Retained Earnings | ($132.31M) | ($109.61M) | ($84.98M) | ($62.77M) | ($43.94M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($18.64M) | ($13.87M) | ($19.00M) | ($13.97M) | ($2.36M) |
| Investing Cash Flow | ($595.0K) | ($640.0K) | $8.19M | ($677.0K) | ($261.0K) |
| Financing Cash Flow | $4.67M | $28.79M | $5.26M | ($509.0K) | $1.57M |
| CapEx | $245.0K | $655.0K | $301.0K | $569.0K | $131.0K |
| Free Cash Flow | ($18.89M) | ($14.52M) | ($19.30M) | ($14.54M) | ($2.50M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 67.0% | 78.8% | 31.2% | 40.7% | 32.4% |
| Operating margin | -1942.2% | -690.7% | -2966.0% | -1476.5% | -67.1% |
| EBITDA margin | -1875.5% | -661.5% | -2867.3% | -1476.5% | -67.1% |
| Net margin | -1893.6% | -667.8% | -3020.2% | -1541.3% | -302.8% |
| Free cash flow margin | -1575.5% | -607.1% | -2722.6% | -1189.7% | -44.3% |
| FCF / Net income | 0.83 | 0.91 | 0.90 | 0.77 | 0.15 |
| R&D / Revenue | 1004.3% | 340.2% | 1278.7% | 766.8% | 47.5% |
| SG&A / Revenue | 1004.9% | 429.3% | 1608.0% | 664.4% | 48.5% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -221.3% | -62.5% | -177.3% | -68.7% | -39.9% |
| Return on equity | -400.1% | -73.0% | -317.7% | -91.9% | -45.5% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 1.33 | 7.60 | 1.50 | 4.17 | 13.06 |
| Quick ratio | 1.33 | 7.60 | 1.50 | 4.17 | 13.06 |
| Cash ratio | 1.14 | 7.45 | 1.27 | 2.16 | 9.47 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | - | - | - | -12.9x | -539.7x |
| Equity multiplier | 1.81 | 1.17 | 1.79 | 1.34 | 1.14 |
| Liabilities / Assets | 0.45 | 0.14 | 0.44 | 0.25 | 0.12 |
| Efficiency | |||||
| Asset turnover | 0.12 | 0.09 | 0.06 | 0.04 | 0.13 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | 32d | 13d | 57d | 16d | - |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | 390d | 71d | 477d | - | 62d |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 1567.2x | 743.9x | 43.9x | 29.7x | - |
| P / S | 7417.6x | 6806.6x | 416.9x | 498.4x | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | -49.9% | 237.4% | -42.0% | -78.3% | - |
| Revenue CAGR (3y) | -0.6% | -24.8% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | -57.4% | 752.5% | -55.5% | -72.8% | - |
| Operating income growth (YoY) | -40.9% | 21.4% | -16.5% | -377.6% | - |
| Net income growth (YoY) | -42.1% | 25.4% | -13.7% | -10.5% | - |
| EPS growth (YoY) | 50.8% | 74.3% | -13.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -30.1% | 24.8% | -32.8% | -482.7% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -74.1% | 224.7% | -67.1% | -45.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.20M totalReportable Segment Aggregation Before Other Operating Segment$1.20M · 100.0%
Product / service
$1.20M totalClinical Trial Revenue$954.0K · 79.6%
Contract Manufacturing Revenue$222.0K · 18.5%
Contract Manufacturing Lease Revenue$23.0K · 1.9%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-17.24
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Longeveron Inc. against the 5 most active filers in the same SIC group.